welcome to oneEDSvoice

- a positively charged Ehlers Danlos Syndrome community.
  • join today!

Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)

key information

study id #: NCT02597361

condition: Ehlers-Danlos Syndrome, Vascular Type

status: recruiting


This study aims to verify the hypothesis that patients with Vascular Ehlers Danlos syndrome (vEDS) should benefit of the blockade of angiotensin (Ang) II noxious effects on their vasculature affected by a defect in type III collagen in addition to the effects celiprolol. This randomized, double blind, placebo controlled trial compares the administration of the Ang II type I receptor blocker (ARB) — irbesartan— to placebo over a 2-year period in vEDS patients with the main objective to reduce the incidence of both symptomatic and asymptomatic vascular events.

intervention: Drug: Irbesartan
Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization
Drug: Placebo
Placebo o.d. to match 150mg or 300mg irbesartan tablets

expertly curated content related to this topic